Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Allogeneic dendritic secretomes** is a cell-free biologic preparation derived from the secretomes (secreted factors, including exosomes, cytokines, and proteins) of allogeneic dendritic cells (DCs), designed for immunostimulating and antineoplastic effects. It leverages the paracrine signaling capabilities of DCs to activate antitumor immune responses without the risks associated with live cell therapies, such as graft-versus-host disease. Primarily investigated in oncology, it promotes T-cell activation and immune-mediated tumor killing, with preclinical and early clinical data supporting its use in cancers like glioblastoma and nasopharyngeal carcinoma.[1][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic dendritic secretomes.